1. Capeding MR, Teshome S, Saluja T, et al. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. Vaccine. 2018;36:3794–3801 DOI: https://doi.org/10.1016/j.vaccine.2018.05.038
2. Gibani MM, Britto C, Pollard AJ. Typhoid and paratyphoid fever: a call to action. Curr Opin Infect Dis. 2018; 31:440–448 DOI:10.1097/QCO.0000000000000479
3. Syed KA, Saluja T, Cho H, et al. Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. Clinical Infectious Diseases. 2020;71(S2):S141–50. DOI: 10.1093/cid/ciaa504
4. Haselbeck, A H, Tadesse, B T, Park, J, et al. Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics. Vaccines. 2021; 9: 281. DOI : https://doi.org/10.3390/ vaccines9030281
5. Zuckerman JN, Hatz C, Kantele A. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Review of Vaccines. 2017;0;1-41 DOI: 10.1080/14760584.2017.1374861
6. Amicizia D, Arata L, Zangrillo F, et al. Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®). J Prev Med Hyg. 2017;58:E1-E8
7. Meiring JE, Giubilini A, Savulescu J, et al. Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge. Clinical Infectious Diseases®. 2019;69(S5):S402–7 DOI: 10.1093/cid/ciz630
8. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD001261. DOI: 10.1002/14651858.CD001261.pub4.
9. Islam M T, Im J, Ahmmed F, et al. Use of Typhoid Vi-Polysaccharide Vaccine as a Vaccine Probe to Delineate Clinical Criteria for Typhoid Fever. Am J Trop Med. Hyg. 2020;103(2): 665–671 doi:10.4269/ajtmh.19-0968
10. Chinnasami B, Sadasivam K, Vivekanandhan A, et al. A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children. Journal of Clinical and Diagnostic Research. 2015;9(5):SC01-SC03 DOI: 10.7860/JCDR/2015/13302.5903
11. Medise BE, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S, et al. (2019) Six-month follow up of a randomized clinical trialphase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS ONE 14(2): e0211784. https://doi. org/10.1371/journal.pone.0211784
12. Soedjatmiko, Sitaresmi MN, Hadinegoro SRS, Kartasasmita CB, et al. Jadwal Imunisasi Anak Umur 0 – 18 tahun Rekomendasi Ikatan Dokter Anak Indonesia Tahun 2020. Satgas Imunisasi IDAI. Sari Pediatri 2020;22(4):252-60.
13. Satuan Petugas Imunisasi Persatuan Dokter Spesialis Penyakit Dalam Indonesia. Pedoman Imunisasi pada Orang Dewasa. Jakarta: PB PAPDI; 2017.